Comparing Oruka Therapeutics (ORKA) & Its Rivals

Oruka Therapeutics (NASDAQ:ORKA) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare Oruka Therapeutics to similar companies based on the strength of its valuation, dividends, risk, profitability, earnings, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Oruka Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oruka Therapeutics	N/A	-$5.34 million	-4.49
Oruka Therapeutics Competitors	$552.97 million	$6.13 million	-106.20

Oruka Therapeutics’ rivals have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Oruka Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Oruka Therapeutics Competitors	-1,887.59%	-41.66%	-26.54%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Oruka Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
Oruka Therapeutics Competitors	865	812	1352	23	2.17

Oruka Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 60.17%. As a group, “Diagnostic substances” companies have a potential upside of 42.59%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Oruka Therapeutics is more favorable than its rivals.

Risk & Volatility

Oruka Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ rivals have a beta of 1.29, indicating that their average share price is 29% more volatile than the S&P 500.

Institutional & Insider Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by insiders. Comparatively, 12.6% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Oruka Therapeutics beats its rivals on 10 of the 13 factors compared.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.